Stockman Wealth Management Inc. Purchases 22,199 Shares of Pfizer Inc. (NYSE:PFE)

Stockman Wealth Management Inc. increased its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 8.0% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 299,101 shares of the biopharmaceutical company's stock after purchasing an additional 22,199 shares during the quarter. Pfizer accounts for 1.3% of Stockman Wealth Management Inc.'s holdings, making the stock its 28th biggest position. Stockman Wealth Management Inc.'s holdings in Pfizer were worth $8,656,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of PFE. Marshall Wace LLP grew its stake in shares of Pfizer by 279.3% during the 2nd quarter. Marshall Wace LLP now owns 5,378,173 shares of the biopharmaceutical company's stock worth $150,481,000 after acquiring an additional 8,378,173 shares in the last quarter. Swedbank AB bought a new position in shares of Pfizer during the 1st quarter worth approximately $172,902,000. International Assets Investment Management LLC bought a new position in shares of Pfizer during the 3rd quarter worth approximately $146,481,000. 1832 Asset Management L.P. grew its stake in shares of Pfizer by 24,961.6% during the 2nd quarter. 1832 Asset Management L.P. now owns 2,497,886 shares of the biopharmaceutical company's stock worth $69,891,000 after acquiring an additional 2,487,919 shares in the last quarter. Finally, Robeco Institutional Asset Management B.V. grew its stake in shares of Pfizer by 120.7% during the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 4,498,313 shares of the biopharmaceutical company's stock worth $130,181,000 after acquiring an additional 2,459,666 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Insider Activity

In other Pfizer news, Director Scott Gottlieb bought 1,000 shares of Pfizer stock in a transaction dated Wednesday, October 30th. The stock was bought at an average price of $28.24 per share, with a total value of $28,240.00. Following the completion of the transaction, the director now owns 10,000 shares in the company, valued at $282,400. The trade was a 0.00 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.06% of the stock is currently owned by company insiders.

Pfizer Stock Performance

Shares of NYSE:PFE traded down $0.32 on Friday, hitting $26.72. The company had a trading volume of 55,951,315 shares, compared to its average volume of 38,136,520. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $31.54. The stock has a market cap of $151.42 billion, a price-to-earnings ratio of 36.11, a P/E/G ratio of 0.85 and a beta of 0.67. The stock has a 50 day moving average price of $28.89 and a 200 day moving average price of $28.65. The company has a current ratio of 1.00, a quick ratio of 0.60 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating the consensus estimate of $0.64 by $0.42. The firm had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The company's quarterly revenue was up 31.2% on a year-over-year basis. During the same period in the previous year, the company earned ($0.17) earnings per share. Analysts expect that Pfizer Inc. will post 2.96 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be given a $0.42 dividend. The ex-dividend date is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.29%. Pfizer's payout ratio is presently 227.03%.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Barclays raised their target price on shares of Pfizer from $30.00 to $32.00 and gave the company an "equal weight" rating in a research note on Wednesday, July 31st. Evercore ISI raised shares of Pfizer to a "strong-buy" rating in a research note on Wednesday, October 30th. Sanford C. Bernstein assumed coverage on shares of Pfizer in a research note on Thursday, October 17th. They issued a "market perform" rating and a $32.00 target price for the company. Citigroup assumed coverage on shares of Pfizer in a research note on Friday, October 25th. They issued a "neutral" rating and a $30.00 target price for the company. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $45.00 target price on shares of Pfizer in a research note on Wednesday, October 23rd. Eight equities research analysts have rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, Pfizer presently has an average rating of "Moderate Buy" and an average target price of $33.58.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.